Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI

Core Insights - Lisata Therapeutics is collaborating with the University of Cincinnati to investigate a treatment for endometriosis using Certepetide, a novel cyclic peptide that targets integrins and neuropilin receptors elevated in both solid tumors and endometriosis [1][2]. Company Overview - Certepetide is a nine-amino-acid cyclic peptide that enhances the penetration of anti-cancer drugs in the tumor microenvironment and modifies the immunosuppressive environment by reducing regulatory T cells and increasing cytotoxic T cells [2][3]. - The partnership aims to evaluate the effectiveness of combining Certepetide with the anti-VEGF drug bevacizumab (Avastin) in reducing endometrial lesions and associated pain [3][4]. Research Details - The study will utilize a mouse model developed by the University of Cincinnati, involving approximately 60 mice divided into six groups to test two different doses of bevacizumab alongside intravenous Certepetide [4]. - The experiment will last six weeks, with three weeks for lesion development followed by three weeks of treatment, after which the lesion burden will be assessed [4]. Industry Context - Endometriosis affects about 10% of women of reproductive age globally, translating to approximately 190 million women, and is often under-recognized despite causing severe pain and other life-impacting symptoms [5]. - Current treatments are primarily symptomatic, including non-steroidal analgesics, hormonal modulators, and surgery, indicating a significant unmet need for more effective therapies [5].